Heartflow (NASDAQ:HTFL) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Heartflow (NASDAQ:HTFL) released its quarterly earnings results on Thursday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.08, FiscalAI reports. The business had revenue of $52.59 million during the quarter. The business’s quarterly revenue was up 41.3% compared to the same quarter last year.

Here are the key takeaways from Heartflow’s conference call:

• HeartFlow posted a strong Q1 with revenue of $52.6 million, up 41% year over year, driven by 67% global case growth and strong utilization across both legacy and newly added accounts.
• The company raised full-year 2026 guidance to $228 million-$232 million in revenue and increased Plaque-specific revenue outlook to $19 million-$21 million, citing momentum in FFRct and faster-than-expected Plaque adoption.
• Plaque Analysis appears to be ramping ahead of plan, with management saying account activation is ahead of schedule, coverage reached 75% of covered lives, and the installed base is expected to reach about 1,200 sites by year-end.
• Gross margin improved to 80.5% from 75.3% a year ago, and guidance was lifted to about 81%, supported by AI efficiencies, volume leverage, and a richer mix of higher-margin Plaque revenue.
• HeartFlow highlighted major innovation and evidence milestones, including the launch of PCI Navigator, progress on autonomous processing, and a proprietary database now exceeding 200 million annotated CCTA images, while also planning new trials to expand its long-term market opportunity.

Heartflow Trading Down 10.7%

Heartflow stock traded down $3.46 during trading hours on Friday, reaching $28.78. 1,272,531 shares of the stock were exchanged, compared to its average volume of 1,384,649. The company has a market cap of $2.48 billion and a P/E ratio of -14.54. Heartflow has a twelve month low of $20.13 and a twelve month high of $41.22. The stock has a 50 day moving average of $27.19 and a two-hundred day moving average of $28.87.

Wall Street Analyst Weigh In

HTFL has been the topic of several research reports. William Blair assumed coverage on shares of Heartflow in a research note on Monday, May 4th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, March 19th. Wells Fargo & Company increased their price objective on shares of Heartflow from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Canaccord Genuity Group set a $37.00 price objective on shares of Heartflow and gave the stock a “buy” rating in a research note on Friday. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.00.

Insider Activity at Heartflow

In other news, Director Julie A. Cullivan sold 9,122 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $25.00, for a total value of $228,050.00. Following the completion of the transaction, the director owned 27,291 shares of the company’s stock, valued at approximately $682,275. This represents a 25.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Campbell Rogers sold 64,533 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $24.64, for a total transaction of $1,590,093.12. Following the completion of the transaction, the insider directly owned 81,002 shares of the company’s stock, valued at $1,995,889.28. This trade represents a 44.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,205,874 shares of company stock worth $64,166,729 over the last three months. 7.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its holdings in shares of Heartflow by 20.8% in the fourth quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock worth $171,812,000 after acquiring an additional 1,014,006 shares during the last quarter. Baillie Gifford & Co. bought a new position in Heartflow in the 3rd quarter valued at approximately $101,182,000. Bamco Inc. NY raised its holdings in Heartflow by 86.2% in the 4th quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock valued at $67,158,000 after buying an additional 1,066,371 shares during the last quarter. Schusterman Interests LLC bought a new position in Heartflow in the 3rd quarter valued at approximately $65,274,000. Finally, Capricorn Investment Group LLC bought a new position in Heartflow in the 4th quarter valued at approximately $48,178,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.